Efecto de la atorvastatina sobre la expresión vascular de los PPAR en conejos dislipémicos

Berliner, 1995, Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics, Circulation, 91, 2488, 10.1161/01.CIR.91.9.2488 Dart, 1999, Lipids and the endothelium, Cardiovasc Res, 43, 308, 10.1016/S0008-6363(99)00150-9 Aengevaeren, 1999, Beyond lipid. The role of th endothelium in coronary artery disease, Atherosclerosis, 147, S11, 10.1016/S0021-9150(99)00250-6 Haller, 1997, Endothelial function: general considerations, Drugs, 53, 1, 10.2165/00003495-199700531-00003 Aragoncillo, 2000, The protective role of atrovastatin on function, structure and ultrastructure in the aorta of dyslipidemic rabbits, Virchow Arc, 437, 545, 10.1007/s004280000278 Oubiña, 2003, Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methyl-inhition on inflammatory markers in atherosclerotic rabbits, Clin Sci, 105, 655, 10.1042/CS20030127 Von der Thusen, 2003, Interleukins in atherosclerosis: molecular pathways and therapeutic potential, Pharmacol Rev, 55, 133, 10.1124/pr.55.1.5 Crisby, 2003, Modulation of the inflammatory process by statins, Drugs Today (Barc), 39, 137, 10.1358/dot.2003.39.2.740209 Takemoto, 2001, Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, Arterioscler Thromb Vasc Biol, 21, 1712, 10.1161/hq1101.098486 Ito, 2006, Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction, Pharmacotherapy, 7, 85S, 10.1592/phco.26.7part2.85S Lahera, 2007, Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins, Curr Med Chem, 14, 243, 10.2174/092986707779313381 Brown, 2007, Peroxisome proliferator–activated receptors as transcriptional nodal points and therapeutic targets, Circulation, 115, 518, 10.1161/CIRCULATIONAHA.104.475673 Rizzo, 2006, PPARs and other nuclear receptors in inflammation, Curr Opin Pharmacol, 6, 421, 10.1016/j.coph.2006.03.012 Schiffrin, 2005, Peroxisome-proliferator-activated receptors and cardiovascular remodeling, Am J Physiol Heart Cir Physiol, 288, H1037, 10.1152/ajpheart.00677.2004 Han, 2005, Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-aactivators, Hypertension, 46, 1086, 10.1161/01.HYP.0000187900.36455.4c Vosper, 2002, Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis, Pharmacol Ther, 95, 47, 10.1016/S0163-7258(02)00232-2 Martin, 2001, Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-1, J Clin Invest, 107, 1423, 10.1172/JCI10852 Kleemann, 2004, Evidence for anti-inflammatory activity of statains and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro, Blood, 103, 4188, 10.1182/blood-2003-11-3791 Landrier, 2004, Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent, J Biol Chem, 279, 45512, 10.1074/jbc.M407461200 Paumelle, 2005, Acute antiinflammatory properties of statins involve peroxisome proliferator–activated receptor-a via inhibition of the protein kinase c signaling pathway, Circ Res, 98, 361, 10.1161/01.RES.0000202706.70992.95 Umeji, 2006, Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-g, and aortic stiffness in hypercholesterolemia, Am J Physiol Heart Circ Physiol, 291, H2522, 10.1152/ajpheart.01198.2005 Chomczynski, 1993, A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples, Bio-Techniques, 15, 532 Livak, 2001, Analysis of relative gene expresión data using Real-Time quantitative PCR and the 2-nnCT method, Methods, 25, 402, 10.1006/meth.2001.1262 Tham, 2001, Angiotensin II is associated with activation of NF-kB-mediated genes and down regulation of PPARs, Physiol Genomics, 11, 21, 10.1152/physiolgenomics.00062.2002 Verreth, 2004, Weightloss-associated induction of peroxisome proliferator-activated receptor-g correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice, Circulation, 110, 3259, 10.1161/01.CIR.0000147614.85888.7A Polikandriotis, 2005, Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms, Arterioscler Thromb Vasc Biol, 25, 1810, 10.1161/01.ATV.0000177805.65864.d4 Wang, 2006, Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cells, Atherosclerosis, 187, 265, 10.1016/j.atherosclerosis.2005.09.008 Murakami, 2006, Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC, Biochem Biophys Res Commun, 341, 973, 10.1016/j.bbrc.2006.01.052 Napoli, 2006, Nitric oxide and atherosclerosis: an update, Nitric Oxide, 15, 265, 10.1016/j.niox.2006.03.011 Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 205;45:89-118. Ortego, 1999, Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells, Atherosclerosis, 147, 253, 10.1016/S0021-9150(99)00193-8 Haberbosch, 2006, Statins prevent NF-kappaB transactivation independently of the IKK-pathway in human endothelial cells, Atherosclerosis, 185, 240, 10.1016/j.atherosclerosis.2005.06.019 Planavila, 2005, Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation, Biochem Biophys Acta, 1687, 76 Brown, 2004, Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma, J Clin Invest, 114, 1564, 10.1172/JCI18730